Floatz Rating
D30/100
Confidence
Indicative
Sponsor
M.D. Anderson Cancer Center
Modality
UNKNOWN
Development Phase
Phase 1/2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04785287CT.gov Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Lung Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Bms-986218 (this asset) | M.D. Anderson Cancer Center | P1/2 | D · 30 |
| Cis-Diamminedichloroplatinum Ii | Taiho Oncology, Inc. | P3 | BB |
| OTL-38 | On Target Laboratories, LLC | P4 | BB |
| Etoposide | SystImmune Inc. | P3 | BB |
| Nivolumab | M.D. Anderson Cancer Center | P2 | B |
| Carboplatin | SystImmune Inc. | P3 | B |
| Pembrolizumab | Essen Biotech | P2 | B |
| Lurbinectedin | SystImmune Inc. | P3 | B |
| Durvalumab | University of British Columbia | P2 | B |
+42 more in the Lung Carcinoma cohort
Other indications for Bms-986218
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Castration-Resistant Prostate Carcinoma | — | P2 | C · 33 |
| Metastatic Malignant Neoplasm | — | P1/2 | D · 30 |
| Liver Cancer | — | P1/2 | D · 30 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Bms-986218 in Lung Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/bms-986218-lung-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →